{"id":53518,"date":"2023-02-01T14:04:30","date_gmt":"2023-02-01T13:04:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/"},"modified":"2023-02-01T14:04:30","modified_gmt":"2023-02-01T13:04:30","slug":"miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/","title":{"rendered":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nCombines Miromatrix\u2019s expertise in bioengineered organs with Baxter\u2019s leadership in critical care delivery and organ support therapies\n<\/li>\n<li>\nIncludes intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients suffering from acute liver failure\n<\/li>\n<\/ul>\n<p>EDEN PRAIRIE, Minn. &amp; DEERFIELD, Ill.&#8211;(BUSINESS WIRE)&#8211;Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called <b>miroliver<i>ELAP<\/i> <\/b>that combines a Miromatrix single-use bioengineered liver with Baxter\u2019s <b>PrisMax <\/b>system. Miromatrix submitted an Investigational New Drug (IND) application for <b>miroliver<i>ELAP<\/i><\/b> to the U.S. Food and Drug Administration (FDA) in November 2022, which appears to be the first IND for a bioengineered organ. Miromatrix intends to commence a Phase I clinical trial using <b>miroliver<i>ELAP<\/i><\/b> to treat patients suffering from ALF, following FDA\u2019s decision that the trial may proceed. Baxter is both a collaborator and shareholder of Miromatrix.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/5\/Bxtlogo_300dpi.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/21\/Bxtlogo_300dpi.jpg\"><\/a><\/p>\n<p>\n\u201cMiromatrix believes that <b>miroliver<i>ELAP<\/i> <\/b>has the potential to save and improve the lives of ALF patients while simultaneously increasing the availability of livers for transplant into other patients,\u201d said Jeff Ross, Ph.D., Miromatrix CEO. \u201cWe are excited to be partnering with Baxter to pioneer this next generation innovation in acute care and liver disease.\u201d\n<\/p>\n<p>\nALF is a serious condition with limited clinical interventions. Over 50,000 people in the United States die from liver failure each year,<sup>i<\/sup> often because they cannot receive a liver transplant in time.<sup>ii<\/sup> However, the liver is capable of regenerating itself back to health in certain circumstances, making therapy to support the native liver during ALF highly clinically relevant. <b>Miroliver<i>ELAP<\/i> <\/b>is designed to provide external support to the patient\u2019s native liver as a bridge-to-transplant or bridge-to-recovery, potentially helping to avoid a liver transplant. The <b>miroliver<i>ELAP<\/i><\/b> Phase I clinical trial will serve as a foundational building block to start generating evidence on how this pioneering therapy may help support patients with ALF.\n<\/p>\n<p>\nMiromatrix\u2019s bioengineered liver is designed to replicate key functions of a human liver and is connected to Baxter\u2019s <b>PrisMax<\/b> system outside of the patient\u2019s body to create the <b>miroliver<i>ELAP<\/i><\/b> system. <b>Miroliver<i>ELAP<\/i><\/b> is designed to provide therapeutic support to ALF patients in hopes their native livers will regenerate themselves back to health. Baxter\u2019s <b>PrisMax<\/b> system is designed to help simplify delivery of continuous renal replacement therapy (CRRT) and other therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU). As part of this collaboration, Baxter has created custom software and disposables to run the <b>miroliver<i>ELAP<\/i><\/b><i> <\/i>treatments during the Phase I clinical trial.\n<\/p>\n<p>\n\u201cBaxter is focused on promoting continuous innovation to advance our organ support therapies and further elevate care for patients with ALF and other critical conditions,\u201d said Brian Tufts, Vice President, Acute Therapies at Baxter. \u201cCombining Miromatrix\u2019s pioneering bioengineered organ technology with Baxter\u2019s expertise in critical care delivery and industry-leading <b>PrisMax<\/b> system has the potential to transform care for ALF patients.\u201d\n<\/p>\n<p>\n<strong>About Miromatrix<\/strong>\n<\/p>\n<p>\nMiromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients&#8217; lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company&#8217;s initial development focus is on human livers and kidneys. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DqEkIR4edhmU-Bva_pmY5pketwaViGr1PPbU7Xlde97L91LY12VEGLoPhR6mLl9WhobpiY1j8_a7HPm_P0TdULA%3D%3D&amp;esheet=53295015&amp;newsitemid=20230201005282&amp;lan=en-US&amp;anchor=miromatrix.com&amp;index=1&amp;md5=2dfd95a8cf49d97b7f4f27d8ead06d41\" rel=\"nofollow noopener\" shape=\"rect\">miromatrix.com<\/a>.\n<\/p>\n<p>\n<strong>About Baxter<\/strong>\n<\/p>\n<p>\nEvery day, millions of patients, caregivers and healthcare providers rely on Baxter\u2019s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we\u2019ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter\u2019s employees worldwide are now building upon the company\u2019s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.baxter.com&amp;esheet=53295015&amp;newsitemid=20230201005282&amp;lan=en-US&amp;anchor=www.baxter.com&amp;index=2&amp;md5=3aec9a1e3520dcd488751545947e55b0\" rel=\"nofollow noopener\" shape=\"rect\">www.baxter.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fbaxter_intl&amp;esheet=53295015&amp;newsitemid=20230201005282&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=f5420ff091bc27bd0f18e6036f9f927b\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbaxter-healthcare%2F&amp;esheet=53295015&amp;newsitemid=20230201005282&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=408ae0a3771c258b4993e3df7ecad2cd\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FBaxterInternationalInc%2F&amp;esheet=53295015&amp;newsitemid=20230201005282&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=492d7da23c83661c623d3c198ff4f534\" rel=\"nofollow noopener\" shape=\"rect\">Facebook<\/a>.\n<\/p>\n<p>\n<b>Intended Use for PrisMax in the U.S.<\/b>\n<\/p>\n<p>\nThe <b>PrisMax <\/b>control unit is intended for:\n<\/p>\n<p>\nContinuous Renal Replacement Therapy (CRRT) for patients weighing 20 kg or more with acute renal failure and\/or fluid overload.\n<\/p>\n<p>\nTherapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kg or more with diseases where removal of plasma components is indicated.\n<\/p>\n<p>\nAll treatments administered via the <b>PrisMax <\/b>control unit must be prescribed by a physician.\n<\/p>\n<p>\n<b>Rx Only. <\/b>For safe and proper use of the <b>PrisMax<\/b> device, refer to the full Instructions for Use.\n<\/p>\n<p>\n<b>Cautionary Statement Regarding Forward-Looking Statements<\/b>\n<\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward looking statements of Miromatrix Medical Inc., including statements regarding the potential initiation of <b>miroliver<i>ELAP<\/i> <\/b>clinical trials. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;outlook,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this press release are only predictions and are based largely on Miromatrix\u2019s current business plans, expectations, and projections about future events and financial trends that Miromatrix believes may affect its business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, Miromatrix\u2019s history of significant losses, which it expects to continue; Miromatrix\u2019s limited history operating as a commercial company; Miromatrix\u2019s expectations with respect to the regulatory pathway of its product candidates, Miromatrix\u2019s ability to obtain regulatory approvals for such product candidates, and the anticipated effect of delays in obtaining any such regulatory approvals; Miromatrix\u2019s expectations with respect to preclinical and clinical trial plans for our product candidates, the results of such activities and the safety and efficacy of Miromatrix\u2019s product candidates; Miromatrix\u2019s ability to commercialize its product candidates; Miromatrix\u2019s ability to compete successfully with larger competitors in its highly competitive industry; Miromatrix\u2019s ability to achieve and maintain adequate levels of coverage or reimbursement for any future products it may seek to commercialize; Miromatrix\u2019s expectations regarding its manufacturing capabilities; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including the outbreak of the novel strain of coronavirus, COVID-19; product liability claims; Miromatrix\u2019s ability to establish and maintain intellectual property protection for its products, as well as its ability to operate its business without infringing the intellectual property rights of others; Miromatrix\u2019s ability to attract and retain senior management and key scientific personnel; and other important factors that could cause actual results, performance or achievements to differ materially from those expected or projected. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of Miromatrix\u2019s Form 10-K filed with the U.S. Securities and Exchange Commission and any additional risks presented in its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. Except as expressly required by applicable securities law, Miromatrix disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.\n<\/p>\n<p>\n<b>Miroliver <\/b>and <b>miroliver<i>ELAP<\/i><\/b> are registered trademarks of Miromatrix Medical Inc. Baxter and <b>PrisMax <\/b>are registered trademarks of Baxter International Inc.\n<\/p>\n<p>\n<sup>i<\/sup> American Liver Foundation: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fliverfoundation.org%2Fabout-your-liver%2Ffacts-about-liver-disease%2Fhow-many-people-have-liver-disease%2F%23%3A~%3Atext%3DIn%25202020%252C%252051%252C642%2520adults%2520in%2Cin%2520the%2520U.S%2520in%25202020&amp;esheet=53295015&amp;newsitemid=20230201005282&amp;lan=en-US&amp;anchor=How+Many+People+Have+Liver+Disease%3F&amp;index=6&amp;md5=0c64af5e059d7e421eb3f9943f95acc9\" rel=\"nofollow noopener\" shape=\"rect\">How Many People Have Liver Disease?<\/a>\n<\/p>\n<p>\n<sup>ii<\/sup> American Liver Foundation: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fliverfoundation.org%2Fabout-your-liver%2Ffacts-about-liver-disease%2Fliver-transplantation%2F&amp;esheet=53295015&amp;newsitemid=20230201005282&amp;lan=en-US&amp;anchor=Liver+Transplantation&amp;index=7&amp;md5=1cc8c067ffd535776238c7230e04e521\" rel=\"nofollow noopener\" shape=\"rect\">Liver Transplantation<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Miromatrix Investor Contact:<\/b><br \/>Greg Chodaczek<br \/>\n<br \/>347-620-7010<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#x3a;&#x69;r&#64;&#x6d;&#x69;r&#111;&#x6d;&#x61;t&#114;&#x69;&#x78;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#114;&#64;&#x6d;&#x69;&#114;o&#x6d;&#x61;&#116;r&#x69;&#120;&#46;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<p>\n<b>Miromatrix Media Contact:<\/b><br \/>Christina Campbell<br \/>\n<br \/>612-280-0249<br \/>\n<br \/><a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#67;&#104;&#x72;&#x69;&#x73;&#x74;&#x69;&#x6e;&#x61;&#64;med&#105;&#97;&#45;&#109;&#105;&#x6e;&#x65;&#x66;&#x69;&#x65;&#x6c;&#x64;&#x2e;com\" rel=\"nofollow noopener\" shape=\"rect\">&#x43;&#x68;&#x72;&#x69;&#115;&#116;ina&#x40;&#x6d;&#x65;&#x64;&#105;&#97;-mi&#x6e;&#x65;&#x66;&#x69;&#101;&#108;&#100;&#46;c&#x6f;&#x6d;<\/a>\n<\/p>\n<p>\n<b>Baxter Investor Contact:<\/b><br \/>Clare Trachtman<br \/>\n<br \/>224-948-3020\n<\/p>\n<p>\n<b>Baxter Media Contact:<\/b><br \/>Andrea Johnson<br \/>\n<br \/>224-948-5353<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#x6f;&#x3a;&#x6d;&#x65;&#x64;ia&#64;&#98;&#97;&#x78;&#x74;&#x65;&#x72;&#x2e;co&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#x65;&#100;&#105;a&#x40;&#x62;&#x61;&#120;te&#x72;&#x2e;&#99;&#111;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Combines Miromatrix\u2019s expertise in bioengineered organs with Baxter\u2019s leadership in critical care delivery and organ support therapies Includes intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients suffering from acute liver failure EDEN PRAIRIE, Minn. &amp; DEERFIELD, Ill.&#8211;(BUSINESS WIRE)&#8211;Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53518","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Combines Miromatrix\u2019s expertise in bioengineered organs with Baxter\u2019s leadership in critical care delivery and organ support therapies Includes intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients suffering from acute liver failure EDEN PRAIRIE, Minn. &amp; DEERFIELD, Ill.&#8211;(BUSINESS WIRE)&#8211;Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T13:04:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/21\/Bxtlogo_300dpi.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure\",\"datePublished\":\"2023-02-01T13:04:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/\"},\"wordCount\":1379,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005282\\\/en\\\/460336\\\/21\\\/Bxtlogo_300dpi.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/\",\"name\":\"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005282\\\/en\\\/460336\\\/21\\\/Bxtlogo_300dpi.jpg\",\"datePublished\":\"2023-02-01T13:04:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005282\\\/en\\\/460336\\\/21\\\/Bxtlogo_300dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005282\\\/en\\\/460336\\\/21\\\/Bxtlogo_300dpi.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/","og_locale":"en_US","og_type":"article","og_title":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure - Pharma Trend","og_description":"Combines Miromatrix\u2019s expertise in bioengineered organs with Baxter\u2019s leadership in critical care delivery and organ support therapies Includes intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients suffering from acute liver failure EDEN PRAIRIE, Minn. &amp; DEERFIELD, Ill.&#8211;(BUSINESS WIRE)&#8211;Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-01T13:04:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/21\/Bxtlogo_300dpi.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure","datePublished":"2023-02-01T13:04:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/"},"wordCount":1379,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/21\/Bxtlogo_300dpi.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/","url":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/","name":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/21\/Bxtlogo_300dpi.jpg","datePublished":"2023-02-01T13:04:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/21\/Bxtlogo_300dpi.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230201005282\/en\/460336\/21\/Bxtlogo_300dpi.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/miromatrix-and-baxter-announce-collaborative-research-agreement-aiming-to-advance-care-for-patients-with-acute-liver-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53518"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53518\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}